vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and DNA X, Inc. (SONM). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $16.2M, roughly 1.2× DNA X, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -29.3%, a 28.5% gap on every dollar of revenue. On growth, DNA X, Inc. posted the faster year-over-year revenue change (7.9% vs -25.7%). Over the past eight quarters, DNA X, Inc.'s revenue compounded faster (9.9% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CTMX vs SONM — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $16.2M |
| Net Profit | $-154.0K | $-4.8M |
| Gross Margin | — | 11.2% |
| Operating Margin | -6.9% | -24.5% |
| Net Margin | -0.8% | -29.3% |
| Revenue YoY | -25.7% | 7.9% |
| Net Profit YoY | 97.6% | -89.2% |
| EPS (diluted) | — | $-4.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $16.2M | ||
| Q2 25 | $18.7M | $11.2M | ||
| Q1 25 | $50.9M | $16.7M | ||
| Q4 24 | $38.1M | $15.3M | ||
| Q3 24 | $33.4M | $15.0M | ||
| Q2 24 | $25.1M | $11.5M | ||
| Q1 24 | $41.5M | $9.1M | ||
| Q4 23 | $26.6M | $13.4M |
| Q3 25 | — | $-4.8M | ||
| Q2 25 | $-154.0K | $-7.5M | ||
| Q1 25 | $23.5M | $458.0K | ||
| Q4 24 | $18.9M | $-21.6M | ||
| Q3 24 | $5.7M | $-2.5M | ||
| Q2 24 | $-6.5M | $-6.6M | ||
| Q1 24 | $13.8M | $-2.9M | ||
| Q4 23 | $837.0K | $-1.4M |
| Q3 25 | — | 11.2% | ||
| Q2 25 | — | 7.6% | ||
| Q1 25 | — | 50.0% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 28.2% | ||
| Q2 24 | — | 25.8% | ||
| Q1 24 | — | 31.8% | ||
| Q4 23 | — | 38.1% |
| Q3 25 | — | -24.5% | ||
| Q2 25 | -6.9% | -60.2% | ||
| Q1 25 | 44.4% | 3.9% | ||
| Q4 24 | 46.4% | 55.3% | ||
| Q3 24 | 12.3% | -15.8% | ||
| Q2 24 | -33.7% | -56.2% | ||
| Q1 24 | 28.1% | -29.5% | ||
| Q4 23 | -2.3% | -9.3% |
| Q3 25 | — | -29.3% | ||
| Q2 25 | -0.8% | -66.8% | ||
| Q1 25 | 46.2% | 2.7% | ||
| Q4 24 | 49.6% | -141.6% | ||
| Q3 24 | 17.2% | -16.7% | ||
| Q2 24 | -26.0% | -57.5% | ||
| Q1 24 | 33.3% | -31.9% | ||
| Q4 23 | 3.1% | -10.1% |
| Q3 25 | — | $-4.83 | ||
| Q2 25 | — | $-0.79 | ||
| Q1 25 | — | $0.08 | ||
| Q4 24 | — | $-116.99 | ||
| Q3 24 | — | $-9.32 | ||
| Q2 24 | — | $-1.41 | ||
| Q1 24 | — | $-0.65 | ||
| Q4 23 | — | $-0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $2.1M |
| Total DebtLower is stronger | — | $5.1M |
| Stockholders' EquityBook value | $119.9M | $-701.0K |
| Total Assets | $175.1M | $40.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $2.1M | ||
| Q2 25 | $49.0M | $2.0M | ||
| Q1 25 | $47.6M | $2.1M | ||
| Q4 24 | $38.1M | $5.3M | ||
| Q3 24 | $40.6M | $9.1M | ||
| Q2 24 | $43.2M | $9.6M | ||
| Q1 24 | $36.2M | $9.3M | ||
| Q4 23 | $17.2M | $9.4M |
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $2.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | — | $-701.0K | ||
| Q2 25 | $119.9M | $-1.3M | ||
| Q1 25 | $25.0M | $-1.1M | ||
| Q4 24 | $-456.0K | $-5.7M | ||
| Q3 24 | $-23.5M | $15.3M | ||
| Q2 24 | $-31.2M | $17.5M | ||
| Q1 24 | $-31.7M | $19.8M | ||
| Q4 23 | $-47.4M | $22.4M |
| Q3 25 | — | $40.2M | ||
| Q2 25 | $175.1M | $36.1M | ||
| Q1 25 | $98.5M | $36.0M | ||
| Q4 24 | $120.5M | $39.7M | ||
| Q3 24 | $139.0M | $49.1M | ||
| Q2 24 | $159.2M | $45.9M | ||
| Q1 24 | $184.7M | $42.4M | ||
| Q4 23 | $201.8M | $56.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-7.0M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-7.0M | ||
| Q2 25 | $-15.8M | $-4.9M | ||
| Q1 25 | $-21.0M | $-9.6M | ||
| Q4 24 | $-19.9M | $-4.5M | ||
| Q3 24 | $-20.7M | $-417.0K | ||
| Q2 24 | $-19.5M | $-3.4M | ||
| Q1 24 | $-26.0M | $-168.0K | ||
| Q4 23 | $-22.0M | $-351.0K |
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | $-4.5M | ||
| Q3 24 | $-20.7M | $-554.0K | ||
| Q2 24 | $-19.6M | $-3.4M | ||
| Q1 24 | $-26.2M | $-198.0K | ||
| Q4 23 | $-22.2M | — |
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | -29.6% | ||
| Q3 24 | -62.1% | -3.7% | ||
| Q2 24 | -78.2% | -29.8% | ||
| Q1 24 | -63.1% | -2.2% | ||
| Q4 23 | -83.5% | — |
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.1% | 0.9% | ||
| Q2 24 | 0.4% | 0.3% | ||
| Q1 24 | 0.3% | 0.3% | ||
| Q4 23 | 1.0% | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | -20.97× | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — | ||
| Q4 23 | -26.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
SONM
Segment breakdown not available.
